Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r

Share this content:
Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r
Risk of Adverse Birth Outcomes No Higher With TDF-FTC-LPV/r

WEDNESDAY, April 25, 2018 (HealthDay News) -- For HIV-infected women and their infants, the risk of adverse birth outcomes is similar with tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) compared with zidovudine, lamivudine, and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r) or TDF-FTC with ritonavir-boosted atazanavir (ATV/r), according to a study published in the April 26 issue of the New England Journal of Medicine.

Kathryn Rough, Sc.D., from Harvard Medical School in Boston, and colleagues compared the risks of adverse birth outcomes among infants with in utero exposure to the three regimens, using data from two U.S.-based cohort studies.

The researchers identified 4,646 birth outcomes. Overall, 2.8 percent of infants or fetuses were exposed to TDF-FTC-LPV/r as the initial antiretroviral therapy regimen during gestation. This is in contrast with 11.6 exposed to TDF-FTC-ATV/r and 20.5 percent exposed to ZDV-3TC-LPV/r. Women receiving TDF-FTC-LPV/r had a similar risk of preterm birth (risk ratio, 0.90; 95 percent confidence interval [CI], 0.60 to 1.33) and low birth weight (risk ratio, 1.13; 95 percent CI, 0.78 to 1.64) compared with women receiving ZDV-3TC-LPV/r. Women receiving TDF-FTC-LPV/r had a similar or slightly higher risk of preterm birth (risk ratio, 1.14; 95 percent CI, 0.75 to 1.72) and low birth weight (risk ratio, 1.45; 95 percent CI, 0.96 to 2.17) compared to women receiving TDF-FTC-ATV/r.

"The risk of adverse birth outcomes was not higher with TDF-FTC-LPV/r than with ZDV-3TC-LPV/r or TDF-FTC-ATV/r among HIV-infected women and their infants in the United States," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Progress in HIV Prevention Has Stalled in the United States

CDC: Progress in HIV Prevention Has Stalled in ...

Agency says effective HIV prevention, treatment not reaching those who could most benefit

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in Children

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in ...

All children with sustained unresponsiveness ingested concentrated and baked egg

Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk

Prenatal Vitamin Intake in Early Pregnancy May Cut ...

ASD risk down for children whose mothers took prenatal vitamins during first month of pregnancy

is free, fast, and customized just for you!




Already a member?

Sign In Now »